Altamira Therapeutics Ltd. ( (CYTOF) ) has released its Q2 earnings. Here is a breakdown of the information Altamira Therapeutics Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Altamira Therapeutics Ltd. is a biotech company focused on developing RNA delivery technology, particularly for applications beyond the liver, utilizing its proprietary xPhore platform.
In its first half of 2025 financial report, Altamira Therapeutics highlighted significant advancements in its RNA delivery technology, including the branding of its circular RNA platform as CycloPhore. The company also announced plans for a partial spin-off of its RNA delivery business to attract private equity investment.
Key financial metrics showed a reduction in operating loss by 32.9% to $2.6 million, primarily due to decreased administrative and R&D expenses. Net loss also decreased significantly by 64.6% to $1.5 million, aided by finance income from foreign currency fluctuations. The company is actively pursuing new partnerships and expects to sign additional collaboration agreements within the year.
Altamira’s strategic focus includes advancing its xPhore platform towards industrialization and filing for an Investigational New Drug (IND). The company is also working on transitioning its nasal spray, Bentrio®, to a Class IIa medical device in the EU and expanding its intellectual property portfolio.
Looking ahead, Altamira anticipates a decrease in operating expenses following the spin-off of its RNA delivery business. The company plans to fund its operations through cash reserves, proceeds from the spin-off, and potential partnerships or divestitures of its legacy assets.